Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 9 ... oral transmucosal (sublingual) route. ARX-01 offers a non-invasive alternative to intravenous patient-controlled analgesia (IV PCA) for the management of acute post-operative pain in ... that it has successfully completed an End-of-Phase 2 meeting with the FDA for ARX-01, a drug/device combination product based on the company's proprietary NanoTab™ dosage ... product based on the company's proprietary NanoTab™ dosage form, which enables delivery of sufentanil by the non-invasive oral transmucosal (sublingual) route. ARX-01 offers a ...
2009 NOV 1 ... product categories, including products used in peritoneal dialysis (PD) treatment, intravenous therapies, injectable drugs and anesthesia products. BioScience revenues ... for fixed asset write-offs related to the discontinuation of the company's SOLOMIX drugdelivery system in development, and planned retirement costs associated with the SYNDEO ...
2009 NOV 16 ... distributes nucleic acid drugs systemically, throughout the human body, via simple intravenous infusion. The delivery technology can be applied both to double stranded (siRNA) and ... Bio-Path Holdings, Inc. (OTC BB: BPTH), a publicly traded biotechnology company with drug development operations in Houston, Texas, issued a news release in which the Company ...
2009 NOV 1 ... regarded as safe) material that is already marketed in various drug products for intravenous and oral administration. The Wellcome Trust funding will support the ... CriticalSorb™ technology has the potential to enable the non-invasive delivery of not just human growth hormone but many other biological drugs with at least ...
2009 NOV 2 ... protein were investigated in Rhesus monkeys. The fusion protein was administered as an intravenous injection at doses up to 50 mg/kg over a 60 h period to 56 Rhesus monkeys. The plasma ... neurotrophic factor (GDNF) is a potential therapy for stroke, Parkinson's disease, or drug addiction. However, GDNF does not cross the blood-brain barrier (BBB)," scientists in ... Monkeys of a Monoclonal Antibody-GDNF Fusion Protein for Targeted Blood-Brain Barrier Delivery. Pharmaceutical Research, 2009;26(10):2227-2236). For more information, ...
2009 NOV 2 ... the United States report. "Recent findings Patient-controlled analgesia of intravenous medications was a major advance in drugdelivery technology that allowed opioids to be ...
2009 NOV 9 ... in the quest for safe, accurate, efficient, cost effective, and ready-to-administer intravenous patient doses. It offers unprecedented reduction of medication errors, ISO-compliant ... and inspected how i.v.STATION automatically prepared IV medications from Spanish drug vials in a variety of syringe sizes in less than one week after its delivery to the ...
2009 NOV 16 ... therapy with 20mg Orazol is as therapeutically effective as monthly treatment with the intravenousdrug Zometa® (4mg) based on movements in observed levels of critical bone ... acquired from Elan Corporation, plc. Merrion Pharmaceutical's patented drug delivery technologies increase bioavailability, by improving absorption in the gastrointestinal ...
2009 NOV 16 ... States, "Treatment with low-amperage (200 mu A) electrical current was compared to intravenous doxycycline treatment or no treatment in a rabbit model of Staphylococcus epidermidis ... States, Rochester, Antimicrobials, Body Weight, Chemotherapy, Doxycycline Hyclate, Drug Therapy, Drugs, Experimental Model, Osteomyelitis, Pharmaceuticals, Treatment, Mayo ... body weight three times per day), and electrical current ( n = 15; 200 mu A continuous delivery). Following treatment, rabbits were sacrificed and the tibias quantitatively cultured. ...
2009 NOV 2 ... in Molecular Therapy (Phase I/II and Phase II Studies of Targeted Gene Delivery In Vivo: Intravenous Rexin-G for Chemotherapy-resistant Sarcoma and Osteosarcoma. Molecular Therapy, ... United States, Santa Monica, Biotechnology, Chemotherapy, Clinical Trial Research, DNA, Drug Resistance, Drug Therapy, Gene Therapy, Genetics, Genomics, Molecular Research, ...
2009 NOV 16 ... showed an initial rapid continuous release followed by a slower sustained release. After intravenous injection into mice, the nanoparticles showed a slower elimination rate and a much ... "The aim was to prepare neoglycoprotein-based nanoparticles for targeted drugdelivery to hepatic stellate cells, and to evaluate their characteristics in vitro and ...
2009 OCT 19 ... for administration of biotinylated therapeutic and/or imaging compounds was elucidated. Intravenous or intracranial injection of the virus into BDIX rats led to the production of ... "One of the main objectives of cancer therapy is to enhance the effectiveness of the drug by concentrating it at the target site and to minimize the undesired side effects to ... University of Kuopio. The researchers concluded: "The lentivirus-mediated delivery of the avidin fusion protein thus represents a potential approach for the repeated ...
2009 NOV 1 ... of novel antimicrobial cationic peptides NAB 7061 and NAB 739 in rats following intravenous administration' have been presented. In this recent report, researchers in Melbourne, ... For additional information, contact F.E. Ali, Facility for Anti-infective Drug Development and Innovation, DrugDelivery, Disposition and Dynamics, Monash Institute of ...
2009 NOV 16 ... "Treatment A (continuous infusion) consisted of a single radiolabeled 12-h intravenous infusion of 1.2 mg of rotigotine (0.6 mg of [C-14] and 0.6 mg of unlabeled rotigotine, ... rotigotine was 37%." Cawello and colleagues published their study in Drug Metabolism and Disposition (Absorption, Disposition, Metabolic Fate, and Elimination of ... Agonist Rotigotine in Man: Administration by Intravenous Infusion or Transdermal Delivery. Drug Metabolism and Disposition, 2009;37(10):2055-2060). For additional ...
2009 NOV 24 ... majority of these wormlike micelles remain in the circulation for at least a day after intravenous injection." "NIRF imaging further suggests that filomicelles convect into ... can penetrate into the tumor stroma. To assess a functional effect, the hydrophobic drug paclitaxel (tax) was loaded into both filomicelles and sonication-generated spherical ... their study in Molecular Pharmaceutics (Flexible Filaments for in Vivo Imaging and Delivery: Persistent Circulation of Filomicelles Opens the Dosage Window for Sustained Tumor ...
2009 NOV 9 ... had already done everything they could to save her. She had been given an intravenous infusion of potent clot-busting medicine, a treatment called systemic thrombolysis, but ... effective, but it also appeared much safer than injecting the high-dose thrombolytic drug systemically or directly into the bloodstream where it can circulate throughout the body ... patients dying from PE. The catheter-based technique involves targeted drug delivery, which typically uses a much lower dose of the potent thrombolytic drug because it is ...
2009 NOV 23 ... room with massive blood clots in her lungs. The patient had been given a large-dose intravenous infusion of clot-busing medicine, a treatment called systemic thrombolysis, but that had ... thrombolysis--an interventional radiology treatment that uses targeted image-guided drugdelivery with specially designed catheters to dissolve dangerous blood clots in the ...
